^Ekesbo, Anna; Andrén, Per E.; Gunne, Lars M.; Tedroff, Joakim (јул 1997). „(−)-OSU 6162 inhibits levodopa-induced dyskinesias in a monkey model of Parkinsonʼs disease”.NeuroReport.8 (11): 2567—70.PMID9261828.doi:10.1097/00001756-199707280-00029.CS1 одржавање: Формат датума (веза)}-
^Tedroff, J.; Torstenson, R.; Hartvig, P.; Sonesson, C.; Waters, N.; Carlsson, A.; Neu, H.; Fasth, K.-J.; l�Ngstr�m, B. (април 1998). „Effects of the substituted (S)-3-phenylpiperidine (?)-OSU6162 on PET measurements in subhuman primates: Evidence for tone-dependent normalization of striatal dopaminergic activity”.Synapse.28 (4): 280—7.PMID9517836.doi:10.1002/(SICI)1098-2396(199804)28:4<280::AID-SYN3>3.0.CO;2-5.replacement character у|last9= на позицији 2 (помоћ)CS1 одржавање: Формат датума (веза)
^Tedroff, J.; Ekesbo, A.; Sonesson, C.; Waters, N.; Carlsson, A. (октобар 1999). „Long-lasting improvement following (-)-OSU6162 in a patient with Huntington's disease”.Neurology.53 (7): 1605—6.PMID10534281.doi:10.1212/WNL.53.7.1605.CS1 одржавање: Формат датума (веза)
^Nichols, N.F; Cimini, M.G; Haas, J.V; Staton, B.A; Tedroff, J.; Svensson, K.A (октобар 2002). „PNU-96391A (OSU6162) antagonizes the development of behavioral sensitization induced by dopamine agonists in a rat model for Parkinson's Disease”.Neuropharmacology.43 (5): 817—24.PMID12384167.doi:10.1016/S0028-3908(02)00144-2.CS1 одржавање: Формат датума (веза)
^Tamminga, C.; Carlsson, A. (април 2002). „Partial dopamine agonists and dopaminergic stabilizers, in the treatment of psychosis”.Current Drug Targets. CNS and Neurological Disorders.1 (2): 141—7.PMID12769623.doi:10.2174/1568007024606195.CS1 одржавање: Формат датума (веза)
^Brandt-Christensen, M.; Andersen, M. B.; Fink-Jensen, A.; Werge, T.; Gerlach, J. (јануар 2006). „The substituted (S)-3-phenylpiperidine (−)-OSU6162 reduces apomorphine- and amphetamine-induced behaviour in Cebus apella monkeys”.Journal of Neural Transmission.113 (1): 11—9.PMID15795789.doi:10.1007/s00702-005-0297-1.CS1 одржавање: Формат датума (веза)
^Rung, Johan P.; Carlsson, Arvid; Markinhuhta, Katarina Rydén; Carlsson, Maria L. (јун 2005). „The dopaminergic stabilizers (−)-OSU6162 and ACR16 reverse (+)-MK-801-induced social withdrawal in rats”.Progress in Neuropsychopharmacology and Biological Psychiatry.29 (5): 833—9.PMID15913873.doi:10.1016/j.pnpbp.2005.03.003.CS1 одржавање: Формат датума (веза)
^Natesan, Sridhar; Svensson, Kjell A.; Reckless, Greg E.; Nobrega, José N.; Barlow, Karen B.L.; Johansson, Anette M.; Kapur, Shitij (август 2006). „The Dopamine Stabilizers (S)-(-)-(3-Methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-Methanesulfonylphenyl)-1-propyl-piperidine (ACR16) Show High in Vivo D2 Receptor Occupancy, Antipsychotic-Like Efficacy, and Low Potential for Motor Side Effects in the Rat”.Journal of Pharmacology and Experimental Therapeutics.318 (2): 810—8.PMID16648369.doi:10.1124/jpet.106.102905.CS1 одржавање: Формат датума (веза)
^Seeman P, Guan HC. Dopamine partial agonist action of (-)OSU6162 is consistent with dopamine hyperactivity in psychosis.European Journal of Pharmacology.„2007 Feb 28;557(2-3):151-3”.PMID17157291.
^Lahti, R. A.; Tamminga, C. A.; Carlsson, A. (септембар 2007). „Stimulating and inhibitory effects of the dopamine "stabilizer" (−)-OSU6162 on dopamine D2 receptor function in vitro”.Journal of Neural Transmission.114 (9): 1143—6.PMID17612788.doi:10.1007/s00702-007-0784-7.CS1 одржавање: Формат датума (веза)
^Rung, Johan P.; Rung, Emilia; Helgeson, Lisa; Johansson, Anette M.; Svensson, Kjell; Carlsson, Arvid; Carlsson, Maria L. (јун 2008). „Effects of (−)-OSU6162 and ACR16 on motor activity in rats, indicating a unique mechanism of dopaminergic stabilization”.Journal of Neural Transmission.115 (6): 899—908.PMID18351286.doi:10.1007/s00702-008-0038-3.CS1 одржавање: Формат датума (веза)
^Benaliouad, Faïza; Kapur, Shitij; Natesan, Sridhar; Rompré, Pierre-Paul (јун 2009). „Effects of the dopamine stabilizer, OSU-6162, on brain stimulation reward and on quinpirole-induced changes in reward and locomotion”.European Neuropsychopharmacology.19 (6): 416—30.PMID19269794.doi:10.1016/j.euroneuro.2009.01.014.CS1 одржавање: Формат датума (веза)
^Dyhring T, Nielsen EØ, Sonesson C, Pettersson F, Karlsson J, Svensson P, Christophersen P, Waters N. The dopaminergic stabilizers pridopidine (ACR16) and (-)-OSU6162 display dopamine D(2) receptor antagonism and fast receptor dissociation properties.European Journal of Pharmacology.„2010 Feb 25;628(1-3):19-26”.PMID19919834.
^Carlsson, Maria L.; Burstein, Ethan S.; Kloberg, Angélica; Hansson, Sarah; Schedwin, Arja; Nilsson, Marie; Rung, Johan P.; Carlsson, Arvid (новембар 2011). „I. In vivo evidence for partial agonist effects of (−)-OSU6162 and (+)-OSU6162 on 5-HT2A serotonin receptors”.Journal of Neural Transmission.118 (11): 1511—22.PMID21874578.doi:10.1007/s00702-011-0704-8.CS1 одржавање: Формат датума (веза)
^Burstein, Ethan S.; Carlsson, Maria L.; Owens, Michelle; Ma, Jian-Nong; Schiffer, Hans H.; Carlsson, Arvid; Hacksell, Uli (новембар 2011). „II. In vitro evidence that (−)-OSU6162 and (+)-OSU6162 produce their behavioral effects through 5-HT2A serotonin and D2 dopamine receptors”.Journal of Neural Transmission.118 (11): 1523—33.PMID21866391.doi:10.1007/s00702-011-0701-y.CS1 одржавање: Формат датума (веза)